Analisis In Silico terhadap Profil Aktivitas Biologis Marbofloxacin Berdasarkan Pendekatan Prediksi Komputasi
Authors
-
Yuneka Saristiana
Prodi Pendidikan Profesi Apoteker, Fakultas Ilmu Kesehatan, Universitas Kadiri
-
Fendy Prasetyawan
Prodi Pendidikan Profesi Apoteker, Fakultas Ilmu Kesehatan, Universitas Kadiri
Competing Interests
Farmasi
-
Muhammad Firdaus Alshol
Prodi Farmasi, Fakultas Ilmu Kesehatan, Universitas Kadiri
Competing Interests
Farmasi
-
Herman Herman
Prodi Farmasi, Fakultas Ilmu Kesehatan, Universitas Kadiri
Competing Interests
Farmasi
-
Muhammad Nurul Fadel
Prodi Pendidikan Profesi Apoteker, Fakultas Farmasi, Universitas Muhammadiyah Kudus
Competing Interests
Farmasi
-
Emma Jayanti Besan
Prodi Farmasi, Fakultas Farmasi, Universitas Muhammadiyah Kudus
Competing Interests
Farmasi
DOI:
https://doi.org/10.64595/jmpb.122026.733Keywords:
Marbofloxacin; aktivitas biologis; in silico; PASS Online; fluorokuinolonAbstract
Marbofloxacin merupakan antibiotik golongan fluorokuinolon yang banyak digunakan dalam bidang kedokteran hewan untuk mengatasi berbagai infeksi bakteri. Selain aktivitas antibakteri yang telah diketahui, senyawa ini diperkirakan memiliki berbagai aktivitas biologis lain yang masih memerlukan eksplorasi lebih lanjut. Penelitian ini bertujuan untuk memprediksi profil aktivitas biologis marbofloxacin menggunakan pendekatan in silico. Penelitian dilakukan secara deskriptif dengan memanfaatkan struktur kimia marbofloxacin dalam format SMILES sebagai data masukan pada platform PASS Online. Hasil prediksi dianalisis berdasarkan nilai Probability of Activity (Pa) dan Probability of Inactivity (Pi), dengan aktivitas potensial ditentukan apabila nilai Pa lebih besar daripada Pi. Hasil penelitian menunjukkan bahwa seluruh aktivitas yang diprediksi memenuhi kriteria Pa > Pi. Aktivitas dengan probabilitas tertinggi adalah Antibiotic Quinolone-like (Pa = 0,727), diikuti Antibacterial (Pa = 0,671), Anaphylatoxin receptor antagonist (Pa = 0,542), Neurodegenerative diseases treatment (Pa = 0,530), Antibacterial, ophthalmic (Pa = 0,510), Topoisomerase II inhibitor (Pa = 0,504), dan DNA synthesis inhibitor (Pa = 0,500). Hasil ini menunjukkan bahwa marbofloxacin tidak hanya berpotensi sebagai antibiotik, tetapi juga memiliki kemungkinan aktivitas biologis lain yang layak dikaji lebih lanjut melalui penelitian in vitro maupun in vivo.
Downloads
References
1. Rhouma M, Archambault M, Butaye P. Antimicrobial use and resistance in animals from a One Health perspective. Vet Sci. 2023;10(5):319. https://doi.org/10.3390/vetsci100503192.
2. Sharma A, Singh R, Goyal R, Narayan G, Mishra AK. The rise, fall, and rethink of (fluoro)quinolones: a quick rundown. Antibiotics. 2025;14(7):643. https://doi.org/10.3390/antibiotics140706433.
3. Marbofloxacin PK/PD review: Lorenzutti AM, Vico JP, Himelfarb MA, Litterio NJ, Sánchez Bruni SF, de Lucas JJ. PK/PD analysis by nonlinear mixed-effects modeling of a marbofloxacin dose regimen for treatment of goat mastitis produced by coagulase-negative staphylococci. Animals. 2021;11(12):3353. https://doi.org/10.3390/ani111233534.
4. Gyrase topoisomerase IV old target new antibacterial: Hearnshaw SJ, Maxwell A. Gyrase and topoisomerase IV: recycling old targets for new antibacterials to combat fluoroquinolone resistance. ACS Infect Dis. 2024;10(8):2709–29. https://doi.org/10.1021/acsinfecdis.4c001285.
5. Blondeau JM, Fitch SD. Comparative in vitro killing by pradofloxacin in comparison to ceftiofur, enrofloxacin, florfenicol, marbofloxacin, tildipirosin, tilmicosin and tulathromycin against bovine respiratory bacterial pathogens. Microorganisms. 2024;12(5):1017. https://doi.org/10.3390/microorganisms120510176.
6. Sana SS, Atuahene D, Nagy V, Shaikh AM, Knop R. The rising threat of antibiotic resistance in poultry: veterinary and One Health perspectives. Vet Sci. 2025;12(11):1059. https://doi.org/10.3390/vetsci121110597.
7. Gelalcha BD. Editorial: antimicrobial resistance in veterinary medicine: epidemiology, economic impact, and mitigation strategies. Front Vet Sci. 2026;13:1783072. https://doi.org/10.3389/fvets.2026.17830728.
8. Quan XH, Wang XY, Han CH, Xing XM, Zhang B, Cang HQ. Novel β-lactam antibiotics versus other antibiotics for treatment of complicated urinary tract infections: a systematic review and meta-analysis. Front Pharmacol. 2024;15:1420170. https://doi.org/10.3389/fphar.2024.14201709.
9. Halawa MR, Fadel M, Al-Rabia MW, Behairy A, Nouh NA, Abdo M, et al. Antibiotic action and resistance: updated review of mechanisms, spread, influencing factors, and alternative approaches for combating resistance. Front Pharmacol. 2024;14:1305294. https://doi.org/10.3389/fphar.2023.130529410.
10. Gianquinto E, Aldeghi M, Cole DJ, Guedes RC, Wade RC, Cavalli A, et al. Toward integrative predictive toxicology: advanced methods for drug toxicity and safety prediction. WIREs Comput Mol Sci. 2026;16(1):e70065. https://doi.org/10.1002/wcms.7006511.
11. Vidal-Luengo AM, Saura-Mas S, Grau JM, Ortega-Vallbona R. AMR and One Health: human and veterinary medicine collaboration. Antibiotics. 2025;14(1):38. https://doi.org/10.3390/antibiotics1401003812.
12. Sharma A, Singh R, Goyal R, Narayan G, Mishra AK. Fluoroquinolone resistance: mechanisms, epidemiology, and control. Antibiotics. 2025;14(7):643. https://doi.org/10.3390/antibiotics1407064313.
13. Hearnshaw SJ, Maxwell A. Gyrase and topoisomerase IV: recycling old targets for new antibacterials to combat fluoroquinolone resistance. ACS Infect Dis. 2024;10(8):2709–29. https://doi.org/10.1021/acsinfecdis.4c0012814.
14. Tutone M, Almerico AM. Computational strategies reshaping modern drug discovery. Molecules. 2026;31(2):200. https://doi.org/10.3390/molecules3102020015.
15. Vasava P, Pérez-Santín E, Rodríguez Solana R, et al. Toxicity prediction based on artificial intelligence: a review. Drug Discov Today. 2023;28(7):103372. https://doi.org/10.1016/j.drudis.2023.10337216.
16. Poh WT, Chong RCX. The new paradigm in animal testing - "3Rs alternatives". Regul Toxicol Pharmacol. 2024;153:105705. https://doi.org/10.1016/j.yrtph.2024.10570517.
17. Ferreira FJN, Carneiro AS. AI-driven drug discovery: a comprehensive review. ACS Omega. 2025;10(23):23889–903. https://doi.org/10.1021/acsomega.5c0054918.
18. Lee H, Kim J, Kim JW, Lee Y. Recent advances in AI-based toxicity prediction for drug discovery. Front Chem. 2025;13:1632046. https://doi.org/10.3389/fchem.2025.163204619.
19. Ripa JD, Ali S, Field M, Smithson J, Wangchuk P. From AI-assisted in silico computational design to preclinical in vivo models: a multi-platform approach to small molecule anti-IBD drug discovery. Pharmaceuticals. 2025;18(10):1536. https://doi.org/10.3390/ph1810153620.
20. Bisht A, Avula SK, Sharma A, et al. QSAR-based virtual screening and machine learning for prediction of chemical toxicity: a comprehensive review. RSC Adv. 2024;14(12):8230–50. https://doi.org/10.1039/D3RA08230J21.
21. Zhang J, Li H, Zhang Y, Huang J, Ren L, Zhang C, et al. Computational toxicology in drug discovery: applications of artificial intelligence in ADMET and toxicity prediction. Brief Bioinform. 2025;26(5):bbaf533. https://doi.org/10.1093/bib/bbaf53322.
22. Madden JC, Pawar G, Cronin MTD, et al. Advancing human health risk assessment: the role of new approach methodologies. Front Toxicol. 2025;7:1632941. https://doi.org/10.3389/ftox.2025.163294123.
23. Roman DL, Roman M, Isvoran A. Computational assessment of pharmacological profiles and toxicity of bioactive compounds: a comparative study using multiple in silico platforms. Toxics. 2024;12(9):621. https://doi.org/10.3390/toxics1209062124.
24. Mechanisms antineoplastic fluoroquinolone: Bajak E, Wróbel MH, Dorofeeva AV, Kleczkowska P. Mechanisms of the antineoplastic effects of new fluoroquinolones in 2D and 3D human breast and bladder cancer cell lines. Int J Mol Sci. 2024;25(13):7045. https://doi.org/10.3390/ijms2513704525.
25. Immunomodulatory fluoroquinolone ARDS: Hatem A, El-Sisi AE, Atwa AM, Shahin NN, Wahdan SA. Immunomodulatory effects of fluoroquinolones in community-acquired pneumonia-associated acute respiratory distress syndrome. Biomedicines. 2024;12(4):858. https://doi.org/10.3390/biomedicines1204085826.
26. Amorim AMB, Piochi LF, Gaspar AT, Preto AJ, Rosário-Ferreira N, Moreira IS. Advancing drug safety in drug development: bridging computational predictions for enhanced toxicity prediction. Chem Res Toxicol. 2024;37(6):827–49. https://doi.org/10.1021/acs.chemrestox.3c0035227.
27. Masarone S, Beckwith KV, Wilkinson MR, Tuli S, Lane A, Windsor S, et al. Advancing predictive toxicology: overcoming hurdles and shaping the future. Digit Discov. 2025;4:303–15. https://doi.org/10.1039/D4DD00257A28.
28. Idakwo G, Luo M, Chen M, Hong H, Zhang C. AI-based toxicity prediction in drug discovery: recent advances, challenges, and future perspectives. J Chem Inf Model. 2023;63(20):6198–211. https://doi.org/10.1021/acs.jcim.3c0020029.
29. Bai H, Ma T, Ma R, Li J, Wang Y, Zhou P, et al. Machine learning-enabled drug-induced toxicity prediction. Adv Sci. 2025;12(22):e2413405. https://doi.org/10.1002/advs.20241340530.
30. Flynn NR, Miller GP, Swamidass SJ. Advancements in computational studies of drug toxicity. Front Pharmacol. 2023;14:1230409. https://doi.org/10.3389/fphar.2023.123040931.
31. Çelik İ, Yadav R, Duzgun Z, Albay C, Yadav DK, Dogan R. Current perspectives and trend of computer-aided drug design: a review and bibliometric analysis. J Biomol Struct Dyn. 2024;42(10):5079–91. https://doi.org/10.1080/07391102.2023.222267832.
32. Wu L, Yan B, Han J, Li R, Xiao J, He S, et al. TOXRIC: a comprehensive database of toxicological data and benchmarks. Nucleic Acids Res. 2023;51(D1):D1432–45. https://doi.org/10.1093/nar/gkac107433.
33. Gao Y, Guo L, Han Y, Zhang J, Dai Z, Ma S. A combination of in silico ADMET prediction, in vivo toxicity evaluation, and potential mechanism exploration of brucine and brucine N-oxide: a comparative study. Molecules. 2023;28(3):1341. https://doi.org/10.3390/molecules2803134134.
34. Kania MK, Zadora PK, Rogala MK. Application of bioinformatics tools in network pharmacology and in silico research: SwissTargetPrediction, PASS Online, STRING, GeneCards, and CTD for anti-inflammatory compound analysis. Comput Biol Med. 2025;178:108687. https://doi.org/10.1016/j.compbiomed.2025.10868735.
35. Banerjee P, Kemmler E, Dunkel M, Preissner R. ProTox 3.0: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 2024;52(W1):W513–20. https://doi.org/10.1093/nar/gkae30336.
36. Braga RC, Alves VM, Muratov EN, Andrade CH, Tropsha A. Machine learning in toxicological sciences: opportunities for assessing drug toxicity. Front Drug Discov. 2024;4:1336025. https://doi.org/10.3389/fddsv.2024.133602537.
37. Jain S, Manganelli S, Gryshkova V, Rodrigues MA, Magarkar A. Methods in predictive toxicology 2023. Front Pharmacol. 2025;16:1556352. https://doi.org/10.3389/fphar.2025.155635238.
38. Yıldız MF, Ertürk AS, Aydemir E. Advances in computer-aided drug design: from molecular docking to AI-driven therapeutic discovery. Comput Biol Chem. 2026;115:108352. https://doi.org/10.1016/j.compbiolchem.2026.10835239.
39. Fu L, Shi S, Yi J, Wang N, He Y, Wu Z, et al. ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support. Nucleic Acids Res. 2024;52(W1):W422–31. https://doi.org/10.1093/nar/gkae23640.
40. Ru J, Sun H, Pan L, Xue Y, Wang J. In silico methods for drug-target interaction prediction. Cell Rep Methods. 2025;5(9):101432. https://doi.org/10.1016/j.crmeth.2025.101432
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2026 Journal of Marine Pharmacy and Biomedicine
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
